-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Miromatrix Medical (NASDAQ:MIRO) Trading Down 3.6%
Miromatrix Medical (NASDAQ:MIRO) Trading Down 3.6%
Miromatrix Medical Inc. (NASDAQ:MIRO – Get Rating) shares traded down 3.6% during mid-day trading on Monday . The company traded as low as $3.26 and last traded at $3.26. 732 shares were traded during mid-day trading, a decline of 95% from the average session volume of 13,489 shares. The stock had previously closed at $3.38.
Analysts Set New Price Targets
Separately, Piper Sandler increased their target price on Miromatrix Medical from $8.00 to $9.00 and gave the stock an "overweight" rating in a report on Monday, November 14th.
Get Miromatrix Medical alerts:Miromatrix Medical Trading Down 3.6 %
The firm has a 50 day simple moving average of $3.65 and a 200 day simple moving average of $3.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 8.09 and a current ratio of 8.09. The firm has a market cap of $68.13 million, a P/E ratio of -2.35 and a beta of -0.35.
Miromatrix Medical (NASDAQ:MIRO – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.04). Miromatrix Medical had a negative return on equity of 65.37% and a negative net margin of 91,903.22%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.01 million. On average, equities research analysts predict that Miromatrix Medical Inc. will post -1.48 EPS for the current fiscal year.Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Envestnet Asset Management Inc. purchased a new stake in Miromatrix Medical during the second quarter valued at $54,000. Legacy Wealth Asset Management LLC bought a new position in shares of Miromatrix Medical in the second quarter worth about $54,000. State Street Corp bought a new position in Miromatrix Medical during the first quarter valued at approximately $93,000. BlackRock Inc. boosted its stake in Miromatrix Medical by 98.5% during the first quarter. BlackRock Inc. now owns 30,139 shares of the company's stock valued at $119,000 after buying an additional 14,958 shares during the last quarter. Finally, Merit Financial Group LLC bought a new position in Miromatrix Medical during the fourth quarter valued at approximately $182,000. 16.87% of the stock is owned by institutional investors.
Miromatrix Medical Company Profile
(Get Rating)
Miromatrix Medical Inc, a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells.
Further Reading
- Get a free copy of the StockNews.com research report on Miromatrix Medical (MIRO)
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
Receive News & Ratings for Miromatrix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miromatrix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
纳斯达克(代码:Miro-Get)股价周一午盘下跌3.6%。该公司股价低至3.26美元,最新报3.26美元。午盘成交量为732股,较13,489股的平均日成交量下降95%。该股此前收盘价为3.38美元。
分析师设定新的价格目标
另外,派珀·桑德勒在11月14日(周一)的一份报告中将其对MiroMatrix Medical的目标价从8.00美元上调至9.00美元,并给予该股“增持”评级。
到达微矩阵医疗警报:MiroMatrix医疗集团股价下跌3.6%
该公司的50日简单移动均线切入位为3.65美元,200日简单移动均线切入位为3.55美元。该公司的负债权益比率为0.10,速动比率为8.09,流动比率为8.09。该公司的市值为6813万美元,市盈率为-2.35,贝塔系数为-0.35。
米罗矩阵医疗(纳斯达克:MIRO-GET评级)上一次公布季度收益是在11月14日星期一。该公司公布了该季度每股收益(0.37美元),低于分析师普遍预期的(0.33美元)和(0.04美元)。MiroMatrix医疗公司的净资产回报率为负65.37%,净利润率为负91903.22%。该公司本季度营收为10万美元,高于分析师预期的10万美元。股票研究分析师平均预测,MiroMatrix Medical Inc.本财年每股收益将为1.48欧元。机构资金流入和流出
对冲基金和其他机构投资者最近调整了对该公司的持股。Envestnet Asset Management Inc.在第二季度购买了MiroMatrix Medical的新股份,价值5.4万美元。Legacy Wealth Asset Management LLC在第二季度购买了MiroMatrix Medical的新头寸,价值约54,000美元。道富集团在第一季度购买了MiroMatrix Medical的一个新头寸,价值约93,000美元。贝莱德股份有限公司在第一季度增持了米罗矩阵医疗98.5%的股份。贝莱德股份有限公司现在持有30,139股该公司股票,价值119,000美元,该公司在上个季度又购买了14,958股。最后,Merit Financial Group LLC在第四季度购买了MiroMatrix Medical的一个新头寸,价值约为182,000美元。16.87%的股票由机构投资者持有。
MiroMatrix医疗公司简介
(获取评级)
MiroMatrix医疗公司是一家生命科学公司,开发了一种用于完全可移植器官的生物工程新技术。它的专利技术是一个平台,使用脱细胞和再细胞的两步法,旨在从猪的器官中移除猪细胞,并用未经修饰的人类细胞取代它们。
进一步阅读
- 免费获取StockNews.com关于MiroMatrix Medical(Miro)的研究报告
- 沃尔格林靴子联盟的收益低于预期对投资者有利吗?
- 为什么华纳兄弟探索成为标准普尔最热门的股票
- Pinterest是2023年值得关注的社交商务平台
- 2023年4大高收益股利之王
- 2023年对固特异轮胎库存来说会是一个好年份吗?
接受MiroMatrix医学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对MiroMatrix Medical和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧